Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)

To date, the ketamine/PCP model of psychosis has been proposed to be one of the best pharmacological models to mimic schizophrenic psychosis in healthy volunteers, since ketamine can induce both positive and negative symptoms of schizophrenia. At subanesthetic doses, ketamine has been reported to primarily block N-methyl-D-aspartate (NMDA) receptor complex giving support to a glutamate deficiency hypothesis in schizophrenia. Positron emission tomography was used to study ketamine-induced psychotic symptom formation in relation to cerebral metabolic alterations in healthy volunteers. Our study shows that NMDA receptor blockade results in a hyperfrontal metabolic pattern. Increased metabolic activity in the frontomedial and anterior cingulate cortex correlated positively with psychotic symptom formation, in particular with ego pathology. Analysis of correlations between syndrome scores and metabolic rate of glucose (CMRglu) or metabolic gradients (ratios) revealed that each psychopathological syndrome was associated with a number of metabolic alterations in cortical and subcortical brain regions, suggesting that not a single brain region, but distributed neuronal networks are involved in acute psychotic symptom formation.

[1]  J. Olney,et al.  NMDA antagonist neurotoxicity: mechanism and prevention. , 1991, Science.

[2]  M. Toru,et al.  Increases in strychnine-insensiive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis , 1994, Biological Psychiatry.

[3]  H. Beech,et al.  The effect of 1-arylcylohexylamine (sernyl) on twelve normal volunteers. , 1960, The Journal of mental science.

[4]  N. Swerdlow,et al.  Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. , 1994, Archives of general psychiatry.

[5]  M. Raichle,et al.  Left globus pallidus abnormality in never-medicated patients with schizophrenia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[6]  James V. Hinrichs,et al.  Ketamine: behavioral effects of subanesthetic doses. , 1984, Journal of clinical psychopharmacology.

[7]  A Carlsson,et al.  Schizophrenia: a subcortical neurotransmitter imbalance syndrome? , 1990, Schizophrenia bulletin.

[8]  N. Volkow,et al.  Patterns of metabolic activity in the treatment of schizophrenia , 1984, Annals of neurology.

[9]  H. Meltzer,et al.  Comparison of Ketamine and Thiopental in Healthy Volunteers: Effects on Mental Status, Mood, and Personality , 1984, Anesthesia and analgesia.

[10]  J. Talairach,et al.  Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .

[11]  M. Piercey,et al.  Dramatic limbic and cortical effects mediated by high affinity PCP receptors. , 1988, Life sciences.

[12]  M. Kozlowski.  Effects of σ agonist compounds on local cerebral glucose utilization: relationship to psychotomimetic properties , 1986, Brain Research.

[13]  O. Paulsen,et al.  Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[14]  S. D. Glick,et al.  Localisation of phencyclidine-induced changes in brain energy metabolism , 1979, Nature.

[15]  N. Volkow,et al.  Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[16]  G. Ma,et al.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. , 1989 .

[17]  Claude Nahmias,et al.  Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by position emission tomography (PET) , 1993, Schizophrenia Research.

[18]  C. Bakker,et al.  Observations on the psychotomimetic effects of Sernyl. , 1961, Comprehensive psychiatry.

[19]  A. Crane,et al.  Local changes in cerebral glucose utilization during ketamine anesthesia. , 1982 .

[20]  Jonathan D. Brodie,et al.  Importance of pharmacologic control in PET studies: Effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia , 1991, Psychiatry Research: Neuroimaging.

[21]  G. Rosenbaum,et al.  Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. , 1959, A.M.A. archives of general psychiatry.

[22]  P. Goldman-Rakic,et al.  Dissociation of object and spatial processing domains in primate prefrontal cortex. , 1993, Science.

[23]  M. Herkenham,et al.  Correlation of regional brain metabolism with receptor localization during ketamine anesthesia: combined autoradiographic 2-[3H]deoxy-D-glucose receptor binding technique. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Domino,et al.  Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man , 1965, Clinical pharmacology and therapeutics.

[25]  J. Keana,et al.  (+)‐[3H]MK‐801 Binding Sites in Postmortem Human Brain , 1990, Journal of neurochemistry.

[26]  M. Bowers,et al.  "Psychedelic" experiences in acute psychoses. , 1966, Archives of general psychiatry.

[27]  E. Metter,et al.  Comparison of PET measurement of local brain glucose metabolism and CAT measurement of brain atrophy in chronic schizophrenia and depression. , 1986, The American journal of psychiatry.

[28]  Karl J. Friston,et al.  Localisation in PET Images: Direct Fitting of the Intercommissural (AC—PC) Line , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  P. Slater,et al.  Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia , 1989, Journal of neurochemistry.

[30]  J D Brodie,et al.  Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. , 1985, The American journal of psychiatry.

[31]  L. DeLisi,et al.  Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: Differences between normal controls and schizophrenic patients , 1987, Biological Psychiatry.

[32]  C. Scharfetter.  Ego-psychopathology: the concept and its empirical evaluation , 1981, Psychological Medicine.

[33]  C. Scharfetter.  Paranoid-halluzinatorische Zustandsbilder bei drogeninduzierten Psychosen , 1987 .

[34]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[35]  R. Fischer,et al.  A Cartography of the Ecstatic and Meditative States , 1971, Science.

[36]  T. Nabeshima,et al.  Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. , 1989, European journal of pharmacology.

[37]  E. Domino,et al.  Changing Concepts in Pain Control During Surgery: Dissociative Anesthesia With CI‐581 A Progress Report , 1968, Anesthesia and analgesia.

[38]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[39]  D. Swandulla,et al.  Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. , 1992, European journal of pharmacology.

[40]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[41]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[42]  D R Medoff,et al.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.

[43]  H. Sass,et al.  [Psychedelic experiences at the onset of productive episodes of endogenous psychoses]. , 1994, Der Nervenarzt.

[44]  E. London,et al.  Alterations in local cerebral glucose utilization induced by phencyclidine , 1987, Brain Research.

[45]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[46]  A. Alavi,et al.  Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography. , 1987, Archives of general psychiatry.

[47]  M S Buchsbaum,et al.  Glucose Metabolic Rate in Normals and Schizophrenics During the Continuous Performance Test Assessed by Positron Emission Tomography , 1990, British Journal of Psychiatry.

[48]  J. Deakin,et al.  Alterations in phencyclidine and sigma binding sites in schizophrenic brains Effects of disease process and neuroleptic medication , 1991, Schizophrenia Research.

[49]  R. Biersner,et al.  Attention, Learning, and Personality During Ketamine Emergence: A Pilot Study , 1975, Anesthesia and analgesia.

[50]  L. DeLisi,et al.  Increased temporal lobe glucose use in chronic schizophrenic patients , 1989, Biological Psychiatry.

[51]  Karl J. Friston,et al.  Plastic transformation of PET images. , 1991, Journal of computer assisted tomography.

[52]  S. Bachneff.  Positron emission tomography and magnetic resonance imaging: A review and a local circuit neurons hypo(dys)function hypothesis of schizophrenia , 1991, Biological Psychiatry.

[53]  S. Potkin,et al.  Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. , 1993, American Journal of Psychiatry.

[54]  E. Bleuler,et al.  Dementia praecox oder Gruppe der Schizophrenien , 1911 .

[55]  M S Buchsbaum,et al.  Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia. , 1982, Archives of general psychiatry.

[56]  N. Volkow,et al.  Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. , 1987, The American journal of psychiatry.

[57]  S. Nelson,et al.  Ketamine-induced changes in regional glucose utilization in the rat brain. , 1980, Anesthesiology.

[58]  M. Spitzer,et al.  Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research , 1992, Biological Psychiatry.

[59]  P. Contreras,et al.  PCP‐induced alterations in cerebral glucose utilization in rat brain: Blockade by metaphit, a PCP‐receptor‐acylating agent , 1987, Synapse.

[60]  G. Rosenbaum,et al.  Model psychoses and schizophrenia. , 1962, The American journal of psychiatry.

[61]  M S Buchsbaum,et al.  Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. , 1992, Archives of general psychiatry.

[62]  C. Nahmias,et al.  Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia , 1989, Psychiatry Research.

[63]  Karl J. Friston,et al.  The left medial temporal region and schizophrenia. A PET study. , 1992, Brain : a journal of neurology.

[64]  D. Lodge,et al.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.

[65]  E. Minder,et al.  Development of a Gas Chromatography‐Mass Spectrometry Method for Determination of Ketamine in Plasma and Its Application to Human Samples , 1995, Therapeutic drug monitoring.

[66]  S. R. Hirsch,et al.  15O POSITRON EMISSION TOMOGRAPHIC SCANNING IN PREDOMINANTLY NEVER-TREATED ACUTE SCHIZOPHRENIC PATIENTS , 1983, The Lancet.

[67]  Barbara B. Collier,et al.  Ketamine and the conscious mind , 1972, Anaesthesia.

[68]  H. Lehmann,et al.  Observations on the Action of Sernyl — A New Psychotropic Drug , 1961, Canadian Psychiatric Association journal.

[69]  P. Wood,et al.  Interactions of Phencyclidine Receptor Agonist MK‐801 with Dopaminergic System: Regional Studies in the Rat , 1990, Journal of neurochemistry.

[70]  H. D. Mummendey.  Das Freiburger Persönlichkeitsinventar (FPI) von J. Fahrenberg und H. Selg , 1971 .

[71]  Karl J. Friston,et al.  Patterns of Cerebral Blood Flow in Schizophrenia , 1992, British Journal of Psychiatry.

[72]  Klaus P. Ebmeier,et al.  Single-photon emission computed tomography with 99mTc-exametazime in unmediated schizophrenic patients , 1993, Biological Psychiatry.

[73]  S. Stone-Elander,et al.  Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates , 1987, Acta psychiatrica Scandinavica.

[74]  A. Alavi,et al.  Regional brain function in schizophrenia. I. A positron emission tomography study. , 1987, Archives of general psychiatry.

[75]  T. Honoré,et al.  Phencyclidine analogues inhibit NMDA-stimulated [3H]GABA release from cultured cortex neurons. , 1987, European journal of pharmacology.

[76]  R. Gur,et al.  Laterality and frontality of cerebral blood flow and metabolism in schizophrenia: Relationship to symptom specificity , 1989, Psychiatry Research.

[77]  A. Catafau,et al.  Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: A resting and activation SPECT study , 1994, Psychiatry Research: Neuroimaging.

[78]  F. Garfield,et al.  A Comparison of Psychologic Responses to Ketamine and Thiopental–Nitrous Oxide–Halothane Anesthesia , 1972, Anesthesiology.

[79]  M. Spitzer,et al.  Beziehungen der Modell- bzw. Drogenpsychosen zu schizophrenen Erkrankungen , 1992 .

[80]  S. Slogoff,et al.  Clinical Experience With Subanesthetic Ketamine , 1974, Anesthesia and analgesia.

[81]  R. Waziri,et al.  Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics , 1991, Biological Psychiatry.

[82]  O. Paulsen,et al.  The chiral forms of ketamine as probes for NMDA receptor functions in humans , 1991 .

[83]  J. Brodie,et al.  Regional brain glucose metabolism in chronic schizophrenia. A positron emission transaxial tomographic study. , 1984, Archives of general psychiatry.

[84]  W. D. Winters,et al.  The cataleptic state induced by ketamine: a review of the neuropharmacology of anesthesia. , 1972, Neuropharmacology.

[85]  T. Hilden,et al.  The psychotropic effect of ketamine. , 1988, Journal of psychoactive drugs.

[86]  P. Wender,et al.  The use of MK-801, a novel sympathomimetic, in adults with attention deficit disorder, residual type. , 1986, Psychopharmacology bulletin.

[87]  T Jones,et al.  In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas , 1983, Annals of neurology.